Dexmedetomidine Pharmacokinetics During Continuous Renal Replacement Therapy (CRRT)

H

Helsinki University Central Hospital (HUCH)

Status and phase

Unknown
Phase 3
Phase 2

Conditions

Acute Kidney Injury

Treatments

Drug: Dexmedetomidine

Study type

Interventional

Funder types

Other

Identifiers

NCT01314209
11102010

Details and patient eligibility

About

The purpose of this study is to determine dexmedetomidine pharmacokinetics during continuous renal replacement therapy on critically ill patients.

Full description

Dexmedetomidine is a selective alpha-2-adrenergic agonist with sedative properties indicated for sedation of patients in the intensive care setting. ICU patients with acute kidney injury requiring renal replacement therapies frequently have changes in volume status causing alterations in drug pharmacokinetics. Although dexmedetomidine pharmacokinetics have been studied earlier on ICU patients, there is no information on its pharmacokinetics in critically ill patients needing continuous renal replacement therapy.

Enrollment

10 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18
  • Clinical need for sedation
  • Acute kidney injury requiring renal replacement therapy (according to ICUs standard operating procedures)

Exclusion criteria

  • Severe bradycardia (HR < 50/min)
  • AV conduction block II-III (unless pacemaker installed)
  • Severe hepatic impairment (bilirubin > 101 umol/l)
  • Pregnancy or lactation
  • Age < 18

Trial design

10 participants in 1 patient group

dexmedetomidine
Experimental group
Treatment:
Drug: Dexmedetomidine

Trial contacts and locations

0

Loading...

Central trial contact

Kirsi-Maija Kaukonen, MD, PhD; Suvi Vaara, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems